- Novo’s Wegovy Beats Lilly’s Zepbound for Heart Health, Study Finds. What It Means for Stocks. Barron’s
- Novo Nordisk’s Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study Reuters
- Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes CNBC
- Weight loss drugs can halve heart patients’ risk of early death, study finds The Guardian
- Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease PR Newswire
Source link
